Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03223155 (A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer), which is not on this map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03223155 phase1active not recruitingnot on this map
A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)
TypeinterventionalSponsorUniversity of ChicagoRan2017 to 2027Enrolled78ConditionsStage IV Small Cell Lung CancerArmsNivolumab, Ipilimumab, Stereotactic body radiation therapy
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Dapeng ChenDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-8109-8879
Liangliang WangThe Laboratory of Microbiome and Microecological Technology, Institute of Microbiology, Chinese Academy of Sciences , Beijing, China.ORCID 0000-0001-8340-5190
Chuangyu WenDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-4416-116X
Andras PiffkoDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-5300-6594
Jason BugnoDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-3046-8072
Xianbin YuDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-7508-8006
Pingluan WangDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-7817-7709
Fei JiDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-7120-3812
Emile Z NaccashaDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0009-0005-5445-9313
Jiaai WangDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-3217-7444
Xiaona HuangDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-9983-5723
Steven J ChmuraDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-8851-7108
Sean P PitrodaDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-3056-7991
Chuan HeDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-4319-7424
Hua Laura LiangDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-5512-8595
Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-5643-8939
Funding
Developing an Oncology Workforce for the 21st Century - Renewal 01K12CA139160 · NCI · UNIVERSITY OF CHICAGO · PI OLOPADE, OLUFUNMILAYO F., SMITH, SONALI · 2010 to 2024
$10.6M
Radiation Effect on Immune Cells and the MicrobiomeU54CA274291 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Joseph O Deasy, Silvia C. Formenti · 2022 to 2026
$9.1M
CLINICAL THERAPEUTICST32GM007019 · NIGMS · UNIVERSITY OF CHICAGO · PI Peter Hugh O'Donnell, MARK J RATAIN · 1985 to 2026
$8.7M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Characterization and modeling of m6A RNA methylation in cancerR01CA251150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIANG, HAN · 2020 to 2024
$2.7M
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapyR01CA262508 · NCI · UNIVERSITY OF CHICAGO · PI WEICHSELBAUM, RALPH R · 2021 to 2025
$2.0M
Chicago Tumor InstituteGerman Research Foundation 455353745Howard Hughes Medical InstituteLudwig Cancer Research FoundationNCI NIH HHS K12 CA139160NCI NIH HHS R01 CA251150NCI NIH HHS R01 CA262508NCI NIH HHS U54 CA274291NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIDA NIH HHS 75N95020D00005NIGMS NIH HHS T32 GM007019NIH HHS 75N93023D00005NIH HHS 75N99020D00005NIH HHS K12CA139160NIH HHS R01CA251150NIH HHS R01CA262508NIH HHS T32GM007019NIH HHS U54CA274291University of Chicago SCR_017760University of Chicago SCR_017914University of Chicago SCR_019196University of Chicago SCR_019197University of Chicago SCR_019199University of Chicago SCR_021806University of Chicago Comprehensive Cancer Center
6 · The paper itself
Abstract
Metastatic progression is a major cause of radiotherapy (RT) failure, yet the mechanisms linking RT to immune suppression and metastasis remain unclear. Here, we identify YTHDF2 as a radiation-induced immune checkpoint in dendritic cells (DCs). By analyzing patient biopsies from a clinical trial (NCT03223155), we discover that increased YTHDF2 expression in DCs after RT correlates with treatment failure after RT. Mechanistically, ionizing radiation induces SPI1, which drives transcription of Ythdf2 in DCs. Upregulated YTHDF2 promotes m6A-mediated degradation of Notch pathway regulators (Mfng, Aph1b, Aph1c), impairing MHC-I cross-presentation and CD8+ T cell activation, thereby facilitating tumor immune evasion and metastatic spread. Crucially, targeting YTHDF2 restores DC immunogenicity, enhances RT-induced tumor control, and improves DC-based cancer vaccines when combined with RT, providing a clinically actionable strategy to overcome RT resistance and metastasis.
Indexed as
CD8-Positive T-LymphocytesCross-PrimingDendritic CellsRadiotherapyRNA-Binding ProteinsT-LymphocytesAnimalsClinical Trials, Phase I as TopicHumansLymphocyte ActivationMiceMice, Inbred C57BLNeoplasmsRandomized Controlled Trials as TopicRNA-Binding Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. · full record | OpenQuestion